Results for Childhood

Dr. Adamson serves as chair of the international consortium Children's Oncology Group and on the National Cancer Advisory Board. In addition to his national and international leadership roles in pediatric oncology, Dr. Adamson maintains a dynamic research program on pediatric clinical-translational drug development, with a strong focus on childhood cancer drug development.

Dr. Mitchell's research aims to explain variations in childhood growth patterns related to the causes and prevention of diseases in later life. This includes studying the impact of behaviors and genes on body composition during development, especially childhood sleep and physical activity behavior.

Dr. Puopolo helped lead the research team that developed and validated multivariate prediction models for neonatal early-onset sepsis risk assessment. Her current research addresses the impacts of maternal immunity, perinatal antibiotic exposure, and neonatal infection on infant and childhood health.

Dr. Maris investigates the molecular and genetic mechanisms contributing to the development and progression of neuroblastoma, a common childhood cancer. He also aims to develop new molecular diagnostic tests and less toxic, targeted therapies to treat relapsed or refractory neuroblastoma, including a major effort in immunotherapy discovery and development.

Dr. Hunger's focuses his research on molecular and genomic approaches to identify and clinically evaluate targeted cancer treatments for children with relapsed or high-risk acute lymphoblastic leukemia (ALL) such as Philadelphia chromosome-like (Ph-Like) ALL. The long-term goal of Dr. Hunger’s research is to develop better therapies, improve cure rates, and minimize treatment toxicities for children with ALL.

Dr. Mukhopadhyay’s research interests include neonatal infectious disease epidemiology, the developing microbiome and the effect of these early-life factors on later childhood health outcomes.

Dr. Mostoufi-Moab's clinical and research program is focused on endocrine late effects after childhood cancer therapy. She has unique dual training in pediatric endocrinology and oncology with a master's degree in clinical epidemiology. The goal of her research program is to pursue a mechanistic understanding of metabolic and endocrine disorders that occur due to cancer therapy.

Dr. Chang is a clinical investigator focusing on cardiovascular assessment and outcomes of pediatric-onset systemic lupus erythematosus (pSLE). Her research assesses the utility of various screening modalities, including echocardiography, ambulatory blood pressure monitoring, and tonometry, for the early detection of cardiovascular disease. Her research goals are to develop screening protocols and targeted interventions to prevent pSLE-related cardiovascular morbidity and mortality.

Dr. Lerman's research interests include non-infectious uveitis and temporomandibular (TMJ) arthritis. Her studies examine the utility of biologic agents to achieve, and maintain, uveitis control. Up to 80 percent of children with juvenile idiopathic arthritis (JIA) have potentially erosive TMJ arthritis, and she is exploring ways to best identify and monitor this often asymptomatic manifestation of JIA.

Dr. Tasian's research centers on the bench-to-bedside investigation of precision medicine therapies for high-risk childhood leukemias.